Chronic Lymphocytic Leukemia | Specialty

The OncLive Chronic Lymphocytic Leukemia condition center page is a comprehensive resource for clinical news and expert insights on treatment advances and ongoing research in chronic lymphocytic leukemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs and updates with chronic lymphocytic leukemia therapy.

BTK Degraders May Be a Promising Approach in CLL/SLL for Patients With Disease Progression

March 6th 2025

Nirav N. Shah, MD, MSHP, and Michael T. Tees, MD, MPH, detail BTK degraders such as NX-5948 under investigation in the CLL/SLL space.

Combination Regimens Expand CLL Treatment Paradigm

March 4th 2025

During an OncLive Peer Exchange at the 2024 ASH Meeting, expert investigators in hematology discussed findings from several clinical trial updates in CLL.

Dr Coombs on the Challenges in Establishing a Treatment Consensus for Relapsed CLL

March 3rd 2025

Catherine C. Coombs, MD, discusses the challenges in establishing a treatment consensus for relapsed CLL.

Five Under 5: Top Oncology Videos for the Week of 2/23

March 2nd 2025

The top 5 videos of the week cover insights in ovarian cancer, NSCLC, CSCC, follicular lymphoma, and CLL.

Pirtobrutinib Earns Positive CHMP Opinion for R/R CLL After a Covalent BTK Inhibitor

February 28th 2025

The CHMP has recommended the European approval of pirtobrutinib for relapsed/refractory CLL previously treated with a covalent BTK inhibitor.

Dr Awan on Patient Characteristics Associated With CAR T-Cell Candidacy in CLL

February 24th 2025

Farrukh Awan, MD, discusses patient characteristics that confer candidacy for CAR T-cell therapy for the management of chronic lymphocytic leukemia.

Time-Limited Zanubrutinib/Rituximab Yields Durable Remissions in Treatment-Naive CLL

February 24th 2025

Time-limited zanubrutinib/rituximab was well tolerated and continued to elicit remissions 13 months after treatment discontinuation in treatment-naive CLL.

Dr Cortese on the Role of Venetoclax in CLL Immune Synapse Repair

February 21st 2025

Matthew Cortese, MD, MPH, discusses the immunologic changes observed with venetoclax in patients with CLL.

Dr Hernandez-Ilizaliturri on the Implications of Immunologic Changes With Venetoclax in CLL

February 19th 2025

Francisco J. Hernandez-Ilizaliturri, MD, details the clinical implications of venetoclax for the treatment of patients with CLL regarding T-cell repair.

Reflections and Future Directions in CLL Management

February 17th 2025

Panelists comment on the increasing preference for fixed-duration therapy over treatment until progression, as reflected in recent guideline updates.

Emerging Agents and Future Strategies in Relapsed/Refractory CLL

February 17th 2025

Panelists discuss the role of non-covalent BTKis in this setting and available supporting data (high level).

Venetoclax Plus Obinutuzumab Improves MRD Clearance in Previously Untreated CLL

February 10th 2025

Venetoclax plus obinutuzumab led to higher undetectable minimal residual disease rates in previously untreated chronic lymphocytic leukemia.

Progression on BTK Inhibitors: Treatment Options and Considerations

February 10th 2025

Panelists comment on the role of combination venetoclax-ibrutinib in this setting and available supporting data.

Relapse After Venetoclax-Based Therapy: Early vs Late Management

February 10th 2025

Panelists review recent ESMO guideline updates for managing early relapse after venetoclax-based time-limited therapy, managing relapse after chemoimmunotherapy or late relapse after venetoclax-based time-limited therapy and defining early versus late relapse.

Venetoclax Elicits Immune Synapse Repair in Chronic Lymphocytic Leukemia

February 7th 2025

Matthew Cortese, MD, MPH, discusses an evaluation of immunologic changes with the treatment of venetoclax in patients with chronic lymphocytic leukemia.

NX-5948 Demonstrates Preliminary Efficacy in High-Risk CLL

February 6th 2025

Alvaro Alencar, MD, discusses the preliminary efficacy and safety of NX-5948, a BTK degrader, in patients with chronic lymphocytic leukemia.

Exploring Novel BCL2i and BTKi Combinations in Frontline CLL Therapy

February 3rd 2025

Panelists discuss the ongoing trials evaluating other BCL2i/BTKi combination approaches.

Managing CLL with TP53 Mutation or del(17p): Guidelines and Strategies

February 3rd 2025

Panelists review recent ESMO guideline updates for the frontline management of patients with CLL and a TP53 or del(17p) mutation.

Comparing Venetoclax-Ibrutinib, Venetoclax-Obinutuzumab, and BTKi Options

January 27th 2025

Panelists discuss the role of ven-ibr in patient populations.

Doublet Therapy With Venetoclax-Ibrutinib: Data and Guidelines

January 27th 2025

Panelists discuss the addition of doublet venetoclax-ibrutinib as a treatment option in ESMO guideline updates.